X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
aged (4) 4
female (4) 4
humans (4) 4
male (4) 4
middle aged (4) 4
antimitotic agents (3) 3
antineoplastic agents (3) 3
clinical trials (3) 3
double-blind method (3) 3
hepatoma (3) 3
index medicus (3) 3
liver cancer (3) 3
niacinamide - analogs & derivatives (3) 3
treatment outcome (3) 3
aged, 80 and over (2) 2
antineoplastic agents - adverse effects (2) 2
antineoplastic agents - therapeutic use (2) 2
cancer (2) 2
carcinoma, hepatocellular - drug therapy (2) 2
care and treatment (2) 2
chemotherapy, adjuvant (2) 2
disease progression (2) 2
hematology, oncology and palliative medicine (2) 2
intention to treat analysis (2) 2
kaplan-meier estimate (2) 2
liver (2) 2
liver diseases (2) 2
liver neoplasms - drug therapy (2) 2
management (2) 2
medical colleges (2) 2
medicine (2) 2
niacinamide - therapeutic use (2) 2
oncology (2) 2
phenylurea compounds - adverse effects (2) 2
phenylurea compounds - therapeutic use (2) 2
sorafenib (2) 2
survival (2) 2
therapy (2) 2
1st-line therapy (1) 1
abdomen (1) 1
abridged index medicus (1) 1
adult (1) 1
angiogenesis (1) 1
antineoplastic agents - administration & dosage (1) 1
antineoplastic combined chemotherapy protocols - therapeutic use (1) 1
antitumor-activity (1) 1
apoptosis - drug effects (1) 1
asia (1) 1
australia (1) 1
bay-43-9006 (1) 1
benzenesulfonates - administration & dosage (1) 1
blaaskanker (1) 1
brivanib (1) 1
bryostatins (1) 1
busulfan - analogs & derivatives (1) 1
busulfan - pharmacology (1) 1
cancer therapies (1) 1
carcinoma, hepatocellular - mortality (1) 1
carcinoma, hepatocellular - pathology (1) 1
carcinoma, hepatocellular - surgery (1) 1
carcinoma, hepatocellular - therapy (1) 1
catheter ablation - adverse effects (1) 1
catheter ablation - mortality (1) 1
cell line (1) 1
chemoembolization, therapeutic - methods (1) 1
clinical-practice guidelines (1) 1
cohort (1) 1
college teachers (1) 1
combined modality therapy (1) 1
controlled trial (1) 1
diagnosis (1) 1
disease-free survival (1) 1
drug dosages (1) 1
embolization (1) 1
endothelial growth-factor (1) 1
europe (1) 1
failure (1) 1
heart attacks (1) 1
hematology (1) 1
hepatectomy - adverse effects (1) 1
hepatectomy - mortality (1) 1
hepatitis (1) 1
hepatocellular carcinoma (1) 1
high-dose chemotherapy (1) 1
hl-60 cells (1) 1
iii trial (1) 1
induced differentiation (1) 1
internal medicine (1) 1
intravenous treosulfan (1) 1
japan (1) 1
lactones - pharmacology (1) 1
leukemia, myeloid, acute - drug therapy (1) 1
leukemia, myeloid, acute - enzymology (1) 1
leukemia, myeloid, acute - pathology (1) 1
lipiodol chemoembolization (1) 1
liver cirrhosis (1) 1
liver neoplasms - mortality (1) 1
liver neoplasms - pathology (1) 1
liver neoplasms - surgery (1) 1
liver neoplasms - therapy (1) 1
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10064, pp. 56 - 66
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1344 - 1354
Summary Background There is no standard of care for adjuvant therapy for patients with hepatocellular carcinoma. This trial was designed to assess the efficacy... 
Hematology, Oncology and Palliative Medicine | CLINICAL-PRACTICE GUIDELINES | DIAGNOSIS | LIVER-TRANSPLANTATION | RISK-FACTORS | THERAPY | MANAGEMENT | ONCOLOGY | SAFETY | PREVENTION | RECURRENCE | Catheter Ablation - mortality | South America | Carcinoma, Hepatocellular - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Hepatectomy - mortality | Antineoplastic Agents - administration & dosage | Protein Kinase Inhibitors - adverse effects | North America | Young Adult | Carcinoma, Hepatocellular - drug therapy | Time Factors | Aged, 80 and over | Liver Neoplasms - pathology | Catheter Ablation - adverse effects | Chemotherapy, Adjuvant | Europe | Risk Factors | Niacinamide - adverse effects | Niacinamide - therapeutic use | Disease Progression | New Zealand | Protein Kinase Inhibitors - administration & dosage | Intention to Treat Analysis | Niacinamide - analogs & derivatives | Liver Neoplasms - mortality | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Adult | Female | Double-Blind Method | Hepatectomy - adverse effects | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Neoplasm Recurrence, Local | Phenylurea Compounds - therapeutic use | Carcinoma, Hepatocellular - surgery | Liver Neoplasms - surgery | Treatment Outcome | Niacinamide - administration & dosage | Disease-Free Survival | Phenylurea Compounds - administration & dosage | Asia | Protein Kinase Inhibitors - therapeutic use | Carcinoma, Hepatocellular - pathology | Aged | Australia | Antimitotic agents | Liver cancer | Medical colleges | Surgery | Liver | Clinical trials | Hepatoma | Antineoplastic agents
Journal Article
European Journal of Cancer, ISSN 0959-8049, 2011, Volume 47, Issue 14, pp. 2117 - 2127
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.